Q-omics provides the consensus-scored HSD11B1L profile across patient tissues and cancer cell-line models. HSD11B1L expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, HSD11B1L is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, HSD11B1L RNA expression shows 17,910 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight HNSC, KIRC, and ACC as cancer lineages where HSD11B1L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HSD11B1L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HSD11B1L survival associations across molecular data types. HSD11B1L RNA expression shows survival associations in the most cancer types (26), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HSD11B1L RNA expression–survival associations across cancer types. High HSD11B1L expression shows unfavorable associations in ACC, UCS, LIHC and MESO, but favorable associations in HNSC and LUAD. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for HSD11B1L RNA expression.
This table summarizes HSD11B1L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for HSD11B1L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HSD11B1L shows lower tumor expression in KIRC and KICH and higher tumor expression in LIHC, CHOL, COAD and KIRP. The KIRC box plot shows higher HSD11B1L RNA expression in normal versus tumor tissue (log2 FC = −0.614, t-test p < 0.001).
This table shows molecular features associated with HSD11B1L in patient tissues and cancer cell lines. In patient samples, HSD11B1L shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, HSD11B1L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
